Netazepide (YF476, Sograzepide) is a potent, selective and orally active gastrin/CCK-2 antagonist with IC50 of 0.1 nM.
Netazepide (YF476, Sograzepide) displays >5,000-fold selectivity over CCK-1 receptors.
Netazepide (YF476, Sograzepide) inhibits pentagastrin-induced gastric acid secretion in anesthetized rats (ED50=87 nM/kg), and shows potential for the treatment of gastroesophageal reflux disease (GERD).
Netazepide (YF476, Sograzepide) also inhibits gastric neuroendocrine enterochromaffin-like (ECL) cell hyperplasia and gastric carcinoid tumor development.
